lipolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== Comparison to SSRIs == As SNRIs were developed more recently than SSRIs, there are relatively few of them. However, the SNRIs are among the most widely used antidepressants today. In 2009, Cymbalta and Effexor were the 11th- and 12th-most-prescribed branded drugs in the United States, respectively. This translates to the 2nd- and 3rd-most-common antidepressants, behind Lexapro (escitalopram), an SSRI. In some studies, SNRIs demonstrated slightly higher antidepressant efficacy than the SSRIs (response rates 63.6% versus 59.3%). However, in one study escitalopram had a superior efficacy profile to venlafaxine. SSRIs do not significantly increase norepinephrine, which is where SNRIs may be used for a greater variety of conditions involving norepinephrine, such as chronic pain disorders. Some additional side effects noted with SNRIs can include increased heart rate and blood pressure. Overall, most patients are able to tolerate both similarly, and their choice depends more on their symptoms, medical history, and previous response to antidepressants.
=== Protein sequence === Resilin was identified to be a product of the Drosophila melanogaster gene CG15920 due to the similarities between amino acid compositions of resilin and the gene product. The Drosophila melanogaster gene is composed of 4 exons, which encode for 4 functional segments in CG15920: signal peptide and 3 peptide encoded by exon 1, 2, and 3. The signal peptide guides pro-resilin into extracellular space, where resilin proteins aggregate and cross link to form a network, and then is cut off from the peptides, so that nascent resilin becomes mature resilin. From the N-terminal, segment encoded by exon 1 contains 18 copies of a 15-residue repeating sequence (GGRPSDSYGAPGGGN); segment corresponding to exon 2 contains 62 amino acids of the chitin-binding Rebers-Riddiford (R-R) consensus sequence (Pfam PF00379); exon 3 encoded peptide is dominated by 11 copies of a 13-residual repeating sequence (GYSGGRPGGQDLG). While enriched glycine and proline in exon 1 and 3 introduce cyclic structures into the protein, tyrosine residuals are able to form di- and tri-tyrosine cross-links between proteins.
=== Combined elementary and middle schools === Pre-kindergarten through grade 8 schools are essentially combined elementary and middle schools, facilitated in one building. Most of these schools are referred to as "academies" in the school district. The elementary school usually starts at pre-kindergarten and ends at grade 5 and the middle school starts at grade 6 and ends at grade 8. These schools usually offer a slightly enhanced standard of learning and studies have suggested that students have benefited from being in one continuous facility from kindergarten through 8th grade, without having the disruption having to attend a brand new school, for the middle school years. Cora L. Rice Elementary School and G. James Gholson Middle School are not true academies. Both schools are housed in one facility but they operate as two completely separate schools for all intents and purposes.
Sources: en.wikipedia.org
=== Grand Lodge of Pennsylvania === Between 1818 and 1822, the Grand Lodge of Pennsylvania chartered three more Lodges in Havana; Las Delicias de la Habana No. 157 on March 2, 1818, La Recompensa de las Virtudes No. 161 on May 9, 1818, La Fidelidad Habanera No. 167 on September 16, 1819, and in Regla, another Lodge named La Union de RegIa No. 166 on April 5, 1819, but all of their charters were revoked by the end of 1822. The Grand Lodge of Pennsylvania chartered two other Lodges at Santiago de Cuba; on November 8, 1820, La Benevolencia No. 175, and on April 1, 1822, The True Philanthropy No. 181. However, these also had their charters revoked in 1826.
== Methods of antibody elution == There are several methods of antibody elution used in clinical blood banking. Some of these methods include manipulating temperature, manipulating pH, use of organic solvents, and chloroquine. Each of these methods have advantages and disadvantages, and the method of elution will vary depending on clinical utility. One of the more commonly used methods is an acid elution, because it is quick, cheap, and relatively easy to perform.
== Selective antagonists == All of the centrally active opioid antagonists used widely in medicine are non-selective, either blocking multiple opioid receptors, or blocking the MOR but activating the KOR. However, for scientific research, selective antagonists are needed which can block one of the opioid receptors but without affecting the others. This has led to the development of antagonists which are highly selective to one of the four receptors:
Sources: en.wikipedia.org
Residues 1-60: An amphipathic N-terminal region dominated by four 11-residue repeats including the consensus sequence KTKEGV. This sequence has a structural alpha helix propensity similar to apolipoproteins-binding domains. It is a highly conserved terminal that interacts with acidic lipid membranes, and all the discovered point mutations of the SNCA gene are located within this terminal. Residues 61-95: A central hydrophobic region which includes the non-amyloid-β component (NAC) region, involved in protein aggregation. This domain is unique to alpha-synuclein among the synuclein family. Residues 96-140: a highly acidic and proline-rich region which has no distinct structural propensity. This domain plays an important role in the function, solubility and interaction of alpha-synuclein with other proteins.
The Metropolitan Police apologise to Doreen Lawrence after failing to provide information about a suspect in her son's murder. Drivers at 16 train operators announce a series of one-day rolling strikes between 7 and 9 May. Co-op Live announces the postponement of its opening events starring Peter Kay as the venue is not ready. 23 April Office for National Statistics data indicates UK government borrowing was at £120.7bn in March 2024, lower than the figure for the same time the previous year, but £6.6bn higher than the government's forecasts. Five migrants including a child are reported to have died attempting to cross the English Channel in a small boat, just hours after passage of the Rwanda Bill. Sunak pledges an additional £500m to support Ukraine, on top of the £2.5bn allocated for this financial year. Sunak announces "the biggest strengthening of our national defence in a generation, to meet the challenge of an increasingly dangerous world". He confirms that defence spending will increase from 2.3% of gross domestic product (GDP) to 2.5% by 2030, meaning an extra £75bn for the military over the next six years. 24 April Four people are injured and several vehicles are damaged as a number of runaway horses – one seemingly covered in blood – escape from the Household Cavalry and gallop through central London. Three people are injured and one arrested after a stabbing incident at a school in Ammanford, Wales. Unions say that 70,000 civil service jobs will be cut in order to fund an increase in defence spending.
Nandrolone is an agonist of the AR, the biological target of androgens like testosterone and DHTTooltip dihydrotestosterone. Unlike testosterone and certain other anabolic steroids, nandrolone is not potentiated in androgenic tissues like the scalp, skin, and prostate, hence deleterious effects in these tissues are lessened. This is because nandrolone is metabolized by 5α-reductase to the much weaker AR ligand 5α-dihydronandrolone (DHN), which has both reduced affinity for the androgen receptor (AR) relative to nandrolone in vitro and weaker AR agonistic potency in vivo. The lack of alkylation on the 17α-carbon drastically reduces the hepatotoxic potential of nandrolone. Estrogen effects resulting from reaction with aromatase are also reduced due to lessened enzyme interaction, but effects such as gynecomastia and reduced libido may still occur at sufficiently high doses. In addition to its AR agonistic activity, unlike many other anabolic steroids, nandrolone is also a potent progestogen. It binds to the progesterone receptor with approximately 22% of the affinity of progesterone. The progestogenic activity of nandrolone serves to augment its antigonadotropic effects, as antigonadotropic action is a known property of progestogens.
Protein therapeutics are proteins used as experimental or approved therapies for disease states. They include "monoclonal antibodies (mAbs), peptide hormones, growth factors, plasma proteins, enzymes, and hemolytic factors" While proteins can be more specific and flexible in their mechanism of action compared to small-molecule drugs, duration of action and drug delivery can be a challenge.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.